Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35643868

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Leukemia
Publication date
2022 Jul
First author
Brümmendorf TH

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Brümmendorf TH
      type
      Author
    2. name
      Cortes JE
      type
      Author
    3. name
      Milojkovic D
      type
      Author
    4. name
      Gambacorti-Passerini C
      type
      Author
    5. name
      Clark RE
      type
      Author
    6. name
      le Coutre P
      type
      Author
    7. name
      Garcia-Gutierrez V
      type
      Author
    8. name
      Chuah C
      type
      Author
    9. name
      Kota V
      type
      Author
    10. name
      Lipton JH
      type
      Author
    11. name
      Rousselot P
      type
      Author
    12. name
      Mauro MJ
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Brümmendorf TH
      type
      Author
    2. name
      Cortes JE
      type
      Author
    3. name
      Milojkovic D
      type
      Author
    4. name
      Gambacorti-Passerini C
      type
      Author
    5. name
      Clark RE
      type
      Author
    6. name
      le Coutre P
      type
      Author
    7. name
      Garcia-Gutierrez V
      type
      Author
    8. name
      Chuah C
      type
      Author
    9. name
      Kota V
      type
      Author
    10. name
      Lipton JH
      type
      Author
    11. name
      Rousselot P
      type
      Author
    12. name
      Mauro MJ
      type
      Author
    bibliography ids
    1. nci-bib-df298bc3829587621115d65c
    book metadata
    content sha256
    ee21de880eb15e1b91cf08a93ca8c39960fdd837988ae40fb42438ed380bc434
    document type
    citation
    dois
    1. 10.1038/s41375-022-01589-y
    electronic publication date
    display
    2022 May 28
    precision
    day
    year
    2022
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:35643868
    immutable id
    pubmed:35643868@ee21de880eb15e1b91cf08a93ca8c39960fdd837988ae40fb42438ed380bc434
    journal
    abbreviation
    Leukemia
    issn electronic
    1476-5551
    issn print
    0887-6924
    issue
    7
    name
    Leukemia
    nlm unique id
    8704895
    pages
    1825-1833
    volume
    36
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      35643868
      provenance
      batch id
      9d150d55960e0c12aada
      provider
      NCBI PubMed ESummary
      record sha256
      57ba036d0bdf2055a5a5f695fae01905b99748e35b18657e376265ba91a9434a
      response sha256
      2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
      retrieved at
      2026-09-09T23:48:09.820498+00:00
      publication date
      display
      2022 Jul
      precision
      month
      year
      2022
      publication types
      1. Journal Article
      2. Multicenter Study
      3. Randomized Controlled Trial
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/35643868/
      title
      Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

      Preserved source evidence · Not medical advice